Abstract
The combination of synthetic and systems biology is a powerful framework to study fundamental questions in biology and produce chemicals of immediate practical application such as biofuels, polymers, or therapeutics. However, we cannot yet engineer biological systems as easily and precisely as we engineer physical systems. In this review, we describe the path from the choice of target molecule to scaling production up to commercial volumes. We present and explain some of the current challenges and gaps in our knowledge that must be overcome in order to bring our bioengineering capabilities to the level of other engineering disciplines. Challenges start at molecule selection, where a difficult balance between economic potential and biological feasibility must be struck. Pathway design and construction have recently been revolutionized by next-generation sequencing and exponentially improving DNA synthesis capabilities. Although pathway optimization can be significantly aided by enzyme expression characterization through proteomics, choosing optimal relative protein expression levels for maximum production is still the subject of heuristic, non-systematic approaches. Toxic metabolic intermediates and proteins can significantly affect production, and dynamic pathway regulation emerges as a powerful but yet immature tool to prevent it. Host engineering arises as a much needed complement to pathway engineering for high bioproduct yields; and systems biology approaches such as stoichiometric modeling or growth coupling strategies are required. A final, and often underestimated, challenge is the successful scale up of processes to commercial volumes. Sustained efforts in improving reproducibility and predictability are needed for further development of bioengineering.
Highlights
The synthesis of urea by Wohler in 18281 established that biological entities are not radically distinct from purely physical ones, we are still unable to design and engineer biological systems with the same ease and precision with which we design physical ones
Environmental applications include microbes that sense, report, and degrade toxic chemicals,[6,7] while synthetic biology has the capability to produce a variety of chemical products ranging from therapeutics to plastics and biofuels.[8,9,10]
We present the difficulties of taking a microbial production process from conception to commercialization along with the tools that can be used to address some of the challenges and gaps in our knowledge and engineering capabilities (Figure 1)
Summary
The synthesis of urea by Wohler in 18281 established that biological entities are not radically distinct from purely physical ones, we are still unable to design and engineer biological systems with the same ease and precision with which we design physical ones (e.g., cell phones, automobiles or jet planes). These may be based on targeted methods as above, or untargeted shotgun proteomic analyses via many “label-free” techniques.[46] A number of recent studies have characterized cellular responses to potential biofuel products[47,48,49,50,51] and identified metabolic sinks that impact carbon utilization.[52] Such analysis will become even more critical as heterologous pathways increase in efficiency, demanding more cellular resources and imposing stresses and constraints on host metabolism.
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.